Risankizumab for Refractory Perianal Fistulizing Crohn's Disease | MicrobiomeTrials← Back to trialsNCT07872449
Risankizumab for Refractory Perianal Fistulizing Crohn's Disease
RecruitingPHASE4INTERVENTIONAL
Trial Details
Start: 2026-10-01Est. Completion: 2028-10-13
Enrollment target: 25 participants Locations- Hyogo Medical University, Nishinomiya, Japan
- Department of Coloproctology, Tokyo Yamate Medical Center, Shinjuku-Ku, Japan
- Department of Inflammatory Bowel Disease (IBD), Yokohama Municipal Citizen's Hospital, Yokohama, Japan
- Inflammatory Bowel Disease Center, YCU Medical Center, Yokohama City University, Yokohama, Japan
Other microbiome trials you might be interested in
Inflammatory Bowel Diseases (IBD)Crohn DiseaseColitis, Ulcerative
Difficult-to-treat inflammatory bowel disease (DTT-IBD) represents a heterogeneous group of patients with treatment-refr…
Multiple LocationsEst. completion Oct 31, 2032
Inflammatory Bowel Disease
This study evaluates oral Lactobacillus reuteri as an adjunct therapy for 2 months. Endoscopic assessments will be perfo…
Suqian, ChinaCompleted Mar 30, 2026
Phase 4
Recruiting
This is an open-label, single-arm, phase 4 study to assess the safety and efficacy of mirikizumab in approximately 60 pa…
Miami, United StatesEst. completion Sep 1, 2027